Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3600027 | 0.82 | MEN1 (0.39) | HCAR2KEAP1NFE2L2ALDH1A1HTT | |
| SCHEMBL6772335 | 0.76 | NFE2L2 (0.52) | HCAR2KEAP1NFE2L2ALDH1A1HTT | |
| SCHEMBL6772333 | 0.76 | NFE2L2 (0.52) | HCAR2KEAP1NFE2L2ALDH1A1HTT | |
| SCHEMBL4026764 | 0.75 | HPGD (0.39) | HPGDSMN1; SMN2L3MBTL1USP2 | |
| SCHEMBL1144905 | 0.75 | NFE2L2 (0.50) | HCAR2KEAP1NFE2L2ALDH1A1HTT | |
| SCHEMBL1144907 | 0.75 | NFE2L2 (0.50) | HCAR2KEAP1NFE2L2ALDH1A1HTT | |
| SCHEMBL5115378 | 0.75 | HCAR2 (0.43) | HCAR2ALDH1A1HTTMAPTLMNA | |
| SCHEMBL3587223 | 0.73 | HCAR2 (0.42) | HCAR2ALDH1A1HTTMAPTLMNA | |
| SCHEMBL303433 | 0.73 | HPGD (0.41) | ALDH1A1HTTMAPTKMT2AMEN1 | |
| SCHEMBL863592 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3740478-B1 | FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2023-11-01 | — | — | EP | disclosed |
| CN-111601799-B | Fused imidazole derivatives as Il-17 modulators | UCB生物制药有限责任公司 | 2023-06-09 | — | — | CN | disclosed |
| US-11472794-B2 | Fused imidazole derivatives as IL-17 modulators | UCB Biopharma SRL (BE) | 2022-10-18 | — | — | US | disclosed |
| US-20220227764-A1 | Imidazopyridine Derivatives as IL-17 Modulators | UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (BE) | 2022-07-21 | — | — | US | disclosed |
| EP-3990459-A1 | IMIDAZOPYRIDINE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2022-05-04 | — | — | EP | disclosed |
| EP-3990451-A1 | FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2022-05-04 | — | — | EP | disclosed |
| CN-114026084-A | Fused imidazole derivatives as IL-17 modulators | UCB生物制药有限责任公司 | 2022-02-08 | — | — | CN | disclosed |
| CN-113906025-A | Imidazopyridine derivatives as IL-17 modulators | UCB生物制药有限责任公司 | 2022-01-07 | — | — | CN | disclosed |
| US-20210053952-A1 | Fused Imidazole Derivatives as IL-17 Modulators | UCB Biopharma SRL (BE) | 2021-02-25 | — | — | US | disclosed |
| WO-2020261141-A1 | IMIDAZOPYRIDINE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020260425-A1 | FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020260426-A1 | FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2020-12-30 | — | — | WO | disclosed |
| EP-3740478-A1 | FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2020-11-25 | — | — | EP | disclosed |
| CN-111601799-A | Fused imidazole derivatives as Il-17 modulators | UCB生物制药有限责任公司 | 2020-08-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11472794-B2 | Fused imidazole derivatives as IL-17 modulators | IL17A, IL2, IL23R | HCAR2 874/4885KEAP1 2798/4885NFE2L2 618/4885 |
| US-20220227764-A1 | Imidazopyridine Derivatives as IL-17 Modulators | IL17A, IL2, IL23R | HCAR2 600/4885KEAP1 2541/4885NFE2L2 643/4885 |
| US-20210053952-A1 | Fused Imidazole Derivatives as IL-17 Modulators | IL17A, IL2, IL23R | HCAR2 874/4885KEAP1 2798/4885NFE2L2 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.